Close Menu

cancer of unknown primary

The partners will use NanoString's PanCancer panel in NCI-sponsored trials to characterize immune activity and develop potentially predictive gene signatures.

The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.

As part of a collaboration with Freenome, Institut Curie will look for correlations between circulating biomarkers and human response to cancer immunotherapies.

The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

The Ontario Institute of Cancer Research-hosted Cancer Genome Collaboratory has amassed 650 TB of data and supported early discovery of mutations.

The companies will combine Empire's NGS services and FISH probe portfolio with Kromatid's Pinpoint probes and directional genomic hybridization technology.

Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.

Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.